1.Meatherall BL, Gregson D, Ross T, Pitout JD, Laupland KB: Incidence, risk factors, and outcomes of Klebsiella pneumoniae bacteremia. Am J Med 2009, 122(9):866–873.
2.Gupta A: Hospital-acquired infections in the neonatal intensive care unit—Klebsiella pneumoniae. Sem Perinatol 2002, 26(5):340–345.
3.Podschun R, Ullmann U: Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998, 11(4):589–603.
4.Tsay RW, Siu LK, Fung CP, Chang FY: Characteristics of bacteremia between community-acquired and nosocomial Klebsiella pneumoniae infection: risk factor for mortality and the impact of capsular serotypes as a herald for community-acquired infection. Arch Intern Med 2002, 162(9):1021–1027.
5.Kang CI, Kim SH, Bang JW, Kim HB, Kim NJ, Kim EC, Oh MD, Choe KW: Community-acquired versus nosocomial Klebsiella pneumoniae bacteremia: clinical features, treatment outcomes, and clinical implication of antimicrobial resistance. J Korean Med Sci 2006, 21(5):816–822.
6.Tawfik AF, Alswailem AM, Shibl AM, Al-Agamy MH: Prevalence and genetic characteristics of TEM, SHV, and CTX-M in clinical Klebsiella pneumoniae isolates from Saudi Arabia. Microb Drug Resist 2011, 17(3):383–388.
7.Feizabadi MM, Delfani S, Raji N, Majnooni A, Aligholi M, Shahcheraghi F, Parvin M, Yadegarinia D: Distribution of bla(TEM), bla(SHV), bla(CTX-M) genes among clinical isolates of Klebsiella pneumoniae at Labbafinejad Hospital, Tehran, Iran. Microb Drug Resist 2010, 16(1):49–53.
8.Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, Bonomo RA: Extended-spectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrob Agents Chemother 2003, 47(11):3554–3560.
9.Rodriguez-Medina N, Barrios-Camacho H, Duran-Bedolla J, Garza-Ramos U: Klebsiella variicola: an emerging pathogen in humans. Emerg Microbes Infect 2019, 8(1):973–988.
10.Nagamura T, Tanaka Y, Terayama T, Higashiyama D, Seno S, Isoi N, Katsurada Y, Matsubara A, Yoshimura Y, Sekine Y et al: Fulminant pseudomembranous enterocolitis caused by Klebsiella oxytoca: an autopsy case report. Acute Med Surg 2019, 6(1):78–82.
11.Goldstein EJ, Lewis RP, Martin WJ, Edelstein PH: Infections caused by Klebsiella ozaenae: a changing disease spectrum. J Clin Microbiol 1978, 8(4):413–418.
12.Laupland KB: Defining the epidemiology of bloodstream infections: the ‘gold standard’ of population-based assessment. Epidemiol Infect 2013, 141(10):2149–2157.
13.Al-Hasan MN, Lahr BD, Eckel-Passow JE, Baddour LM: Epidemiology and outcome of Klebsiella species bloodstream infection: a population-based study. Mayo Clin Proc 2010, 85(2):139–144.
14.Pepin J, Yared N, Alarie I, Lanthier L, Vanasse A, Tessier P, Deveau J, Chagnon MN, Comeau R, Cotton P et al: Klebsiella pneumoniae bacteraemia in a region of Canada. Clin Microbiol Infect 2010, 16(2):141–146.
15.Laupland KB, Pasquill K, Parfitt EC, Naidu P, Steele L: Burden of community-onset bloodstream infections, Western Interior, British Columbia, Canada. Epidemiol Infect 2016, 144(11):2440–2446.
16.Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987, 40(5):373–383.
17.Morin CA, Hadler JL: Population-based incidence and characteristics of community-onset Staphylococcus aureus infections with bacteremia in 4 metropolitan Connecticut areas, 1998. J Infect Dis 2001, 184(8):1029–1034.
18.Friedman ND, Kaye KS, Stout JE, McGarry SA, Trivette SL, Briggs JP, Lamm W, Clark C, MacFarquhar J, Walton AL et al: Health care—associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002, 137(10):791–797.
19.Kroger E, Tourigny A, Morin D, Cote L, Kergoat MJ, Lebel P, Robichaud L, Imbeault S, Proulx S, Benounissa Z: Selecting process quality indicators for the integrated care of vulnerable older adults affected by cognitive impairment or dementia. BMC Health Serv Res 2007, 7:195.
20.Population/Local Health Areas &Facility Profiles. Available at: https://www.interiorhealth.ca/AboutUs/QuickFacts/PopulationLocalAreaProfiles/Pages/default.aspxv accessed April 22, 2019.
21.HIV Monitoring Quartley Report: Interior Health. Available at: http://stophivaids.ca/qmr/2018-Q4/#/iha 2Accessed April 22, 2019
22.Ellison LF, Wilkins K: Canadian trends in cancer prevalence. Health Rep 2012, 23(1):7–16.
23.Prevalence of Chronic Diseases Among Canadian Adults, Public Health Agency of Canada. Available at: https://www.canada.ca/en/public-health/services/chronic-diseases/prevalence-canadian-adults-infographic–2019.html Accessed April 22, 2019..
24.Heart Disease in BC, Cardiac Services BC. Available at: http://www.cardiacbc.ca/health-info/heart-disease-in-bc Accessed April 22, 2019.
25.Stroke in Canada: Highlights from the Canadian Chronic Disease Surveillance System, Public Health Agency of Canada. Available at https://www.canada.ca/en/public-health/services/publications/diseases-conditions/stroke-canada-fact-sheet.html Accessed April 22, 2019.
26.Arora P, Vasa P, Brenner D, Iglar K, McFarlane P, Morrison H, Badawi A: Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey. CMAJ 2013, 185(9):E417–423.
27.Liver Disease in Canada, Canadian Liver Foundation Available at: https://www.liver.ca/wp-content/uploads/2017/09/Liver-Disease-in-Canada-E–3.pdf Accessed April 23, 2019.
28.Lovell M, Harris K, Forbes T, Twillman G, Abramson B, Criqui MH, Schroeder P, Mohler ER, 3rd, Hirsch AT, Peripheral Arterial Disease C: Peripheral arterial disease: lack of awareness in Canada. Can J Cardiol 2009, 25(1):39–45.
29.Wong, R., Davis, A.M., Badley, E., Grewal, R., Mohammed, M: Prevalence of Arthritis and Rhematic Diseases Around the World, 2010. MOCA. Available at: http://www.modelsofcare.ca/pdf/10–02.pdf Accessed April 22, 2019.
30.James R, Hijaz A: Lower urinary tract symptoms in women with diabetes mellitus: a current review. Curr Urol Rep 2014, 15(10):440.
31.Huang CH, Tsai JS, Chen IW, Hsu BR, Huang MJ, Huang YY: Risk factors for in-hospital mortality in patients with type 2 diabetes complicated by community-acquired Klebsiella pneumoniae bacteremia. J Formos Med Assoc 2015, 114(10):916–922.
32.Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, Zhang F, Li S, Wang R, Wang H: High Prevalence of Hypervirulent Klebsiella pneumoniae Infection in China: Geographic Distribution, Clinical Characteristics, and Antimicrobial Resistance. Antimicrob Agents Chemother 2016, 60(10):6115–6120.
33.Li J, Ren J, Wang W, Wang G, Gu G, Wu X, Wang Y, Huang M: Risk factors and clinical outcomes of hypervirulent Klebsiella pneumoniae induced bloodstream infections. Eur J Clin Microbiol Infect Dis 2018, 37(4):679–689.
34.Sanchez-Lopez J, Garcia-Caballero A, Navarro-San Francisco C, Quereda C, Ruiz-Garbajosa P, Navas E, Dronda F, Morosini MI, Canton R, Diez-Aguilar M: Hypermucoviscous Klebsiella pneumoniae: A challenge in community acquired infection. IDCases 2019, 17:e00547.